ArticleCommunications biology2026
Naturally occurring dinactin targets cpsA protein and kills Mycobacterium tuberculosis by disrupting the proton motive force.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Tuberculosis, especially drug-resistant tuberculosis remains a global threat, and new drugs are desperately needed to combat the spread of multidrug-resistant Mycobacterium tuberculosis. Here we describe a natural macrotetrolide dinactin with anti-tuberculosis activity against susceptive and non-replicating Mycobacterium tuberculosis. Dinactin can also synergistically enhance the anti-tuberculosis effect of rifampicin and isoniazid against drug-resistant strains.Furthermore, dinactin exhibited excellently antituberculosis effect in macrophage and Galleria mellonella models. Since the ionophore properties of dinactin, it not only enhanced cations transport and altered membrane permeability but also caused the dissipation of proton motive force and metabolic perturbations. Finally, through the selection of spontaneous resistant mutants and whole genome sequencing, non-synonymous single nucleotide polymorphisms were successfully identified in the cpsA gene of the LytR-Cps2A-Psr family. The dinactin-resistant mutants exhibited decreased in vitro drug sensitivity to dinactin without cross-resistance to first-line antituberculosis drugs. Genetic studies and molecular biology assays have subsequently confirmed cpsA as one of the potential targets for dinactin's anti-tuberculosis activity. Collectively, these data indicate that dinactin could be a promising candidate for treating tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.